Skip Navigation

Annals of Oncology 2006 17(Supplement 2):ii36-ii41; doi:10.1093/annonc/mdj919
This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow CME/CE:
Take the course for this article:
 Annals of Oncology course: part 4 iss...
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (3)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by De Petris, L.
Right arrow Articles by de Marinis, F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by De Petris, L.
Right arrow Articles by de Marinis, F.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2006 European Society for Medical Oncology

symposium article

Treatment of advanced non-small cell lung cancer

L. De Petris1, L. Crinò2, G. V. Scagliotti3, C. Gridelli4, D. Galetta5, G. Metro6, S. Novello3, P. Maione4, G. Colucci5 and F. de Marinis1,7,*

1 5th Pneumo-Oncology Unit, Deparment of Lung Diseases, S. Camillo-Forlanini Hospitals, Rome, Italy; 2 Division of Medical Oncology, Policlinico Hospital, Perugia, Italy; 3 University of Torino, Thoracic Oncology Unit, S. Luigi Hospital, Orbassano, Italy; 4 Medical Oncology Unit, S.G. Moscati Hospital, Avellino, Italy; 5 Medical and Experimental Oncology Unit, Oncology Institute, Bari, Italy; 6 Division of Medical Oncology, Bellaria Hospital, Bologna, Italy; 7 Fo.R.O. (Oncological Research Foundation), Rome, Italy

* Correspondence to: Filippo de Marinis, 5th Pneumo-Oncology Unit, Department of Lung Diseases, S. Camillo-Forlanini Hospitals, Via Portuense 332 – 00149 Rome, Italy. Tel/Fax: +39 06 5555 2565; Email: demarinis.filippo{at}virgilio.it

In the last decade the treatment of advanced-metastatic non-small cell lung cancer has substantially improved. If in the early 90s there was still concern about the real efficacy of chemotherapy over best suppotive care alone in the advanced setting, constant developments in clinical research have demonstrated the survival advantage of active anti-cancer drugs not only in the first-line setting, but, lately, even in patients with recurrent disease after failure of two previous chemotherapy lines. With the premises of high throughput technologies, translational research is aiming to characterize patients and tumors on a molecular basis. With pharmacogenomics it would then be possible to accurately predict patient outcome and tailor the treatment strategy according to the geno-phenotype of single patients.

Key words: non-small cell lung cancer, advanced disease, platinum-based chemotherapy, docetaxel, pemetrexed, EGFR inhibitors, PS 2 patients, pharmacogenomics


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Molecular Cancer TherapeuticsHome page
T. A. Luster, J. A. Carrell, K. McCormick, D. Sun, and R. Humphreys
Mapatumumab and lexatumumab induce apoptosis in TRAIL-R1 and TRAIL-R2 antibody-resistant NSCLC cell lines when treated in combination with bortezomib
Mol. Cancer Ther., February 1, 2009; 8(2): 292 - 302.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
J. Voortman, A. Checinska, G. Giaccone, J. A. Rodriguez, and F. A.E. Kruyt
Bortezomib, but not cisplatin, induces mitochondria-dependent apoptosis accompanied by up-regulation of noxa in the non-small cell lung cancer cell line NCI-H460
Mol. Cancer Ther., March 1, 2007; 6(3): 1046 - 1053.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.